A5064404544- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- PI3K/AKT/mTOR signaling in cancer
- HER2/EGFR in Cancer Research
- Cancer-related molecular mechanisms research
- Drug Transport and Resistance Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related gene regulation
- Liver physiology and pathology
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- MicroRNA in disease regulation
Yonsei University
2016-2025
Seoul National University
2024
Gangnam Severance Hospital
2017
Chong Kun Dang Bio (South Korea)
2015
Yonsei University Health System
2014
Cancer Research Center
2008
Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated safety and efficacy of trastuzumab combined with ramucirumab paclitaxel as second-line treatment HER2-positive G/GEJ cancer.Patients cancer who progressed after trastuzumab-containing were enrolled from five centers in Republic Korea. Patients administered a 28-day cycle (once on days...
Abstract In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet regimen (pembrolizumab, trastuzumab, doublet chemotherapy) as first-line therapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) (NCT02901301). The primary endpoints were recommended dose (RP2D) Ib objective response rate (ORR) II. secondary included progression-free survival (PFS), overall (OS), duration response, time to...
// Byungho Lim 1, * , Chan Kim 2, 3, Jeong-Hwan 4 Woo Sun Kwon 3 Won Seok Lee Jeong Min Jun Yong Park 5 Hyo Song 2 Kyu Hyun Tae Soo Jong-Lyul Cheol Chung 6 Young Rha Seon-Young 7 1 Genome Structure Research Center, Korea Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Division Medical Oncology, Department Internal Medicine, Yonsei Cancer University College Seoul, Song-Dang for Research, Epigenomics Medicine Gastroenterology, Brain 21 Project Science, Functional Genomics, Science...
218 Background: We report the updated clinical data and molecular profiling results of a multi-institutional phase Ib/II trial triple combination (pembrolizumab, trastuzumab, chempotherapy) as first line therapy for HER2 positive advanced gastric gastroesophageal junction (AGC/GEJ) cancer. (PANTHERA trial; NCT02901301). Methods: Pembrolizumab 200mg IV D1, Trastuzumab 6mg/kg (after 8mg/kg load) Capecitabine 1000mg/m 2 bid D1-14, Cisplatin 80mg/m D1 every 3 weeks was selected recommended II...
489 Background: Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) accounts for 5-10% of all cancers and has a relatively favorable prognosis compared to other subtypes. While the genomic profile EBVaGC been previously reported exhibit extensive CpG island methylation, elevated levels PD-L1/2, an absence TP53 mutations, transcriptomic features remain less explored. The response immunotherapy various. This study comprehensively investigates characteristics in relation PD-L1 status....
588 Background: Although histologically defined subtypes exist, renal cell carcinoma (RCC) is a heterogenous disease, resulting in various treatment outcomes and prognosis. Here, we conducted comprehensive profiling of RCC with histopathologic, proteomic, phosphoproteomic, genomic, transcriptomic analyses on tumor paired adjacent normal tissues from 113 patients. Methods: Tumor matched were subjected to proteomic phosphoproteomic analysis (N=113), whole exome sequencing (N=74), (N=70)....
Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance trastuzumab-based front-line chemotherapy in HER2+ GC patients and establish factors predictive of this resistance.Among 129 patients, 25% displayed rapid disease progression within 4 months from initiation therapy. These showed a higher rate signet ring cell histology, bone metastasis, poor performance status, frequent loss PTEN...
Abstract Background Ultra-deep sequencing to detect low-frequency mutations in circulating tumor-derived DNA (ctDNA) increases the diagnostic value of liquid biopsy. The demand for large ctDNA panels comprehensive genomic profiling and tumor mutational burden (TMB) estimation is increasing; however, few TMB have been validated. Here, we designed a panel with 531 genes, named TMB500, along technical clinical validation. Methods Synthetic reference cell-free materials predefined allele...
Objectives Significant variability in the efficacy and toxicity of an anticancer drug is observed cancer patients. Currently, there are no standard tools for prediction a patient's tumor response or his risk adverse events to chemotherapy. Methods We investigate association between polymorphisms gemcitabine metabolism-related genes its chemosensitivity vitro using 62 human cell lines various origins. Polymorphisms deoxycytidine monophosphate deaminase (DCTD), kinase (DCK) ribonucleotide...
Receptor tyrosine kinase MET (c‐MET) has received considerable attention as a potential target for gastric cancer (GC) therapy and number of c‐MET inhibitors have been developed. For successful drug development, proper preclinical studies especially using patient derived cell lines are very important. We profiled ‐related characteristics in 49 GC to utilize them models GC. Forty‐nine were analyzed genetic, biological, molecular status characterize molecules. Four tested elucidate the...
<h3>Background</h3> The aim of this study is to profile the cytokines and immune cells body fluid from metastatic gastric cancer (mGC), evaluate potential role as a prognostic factor feasibility predictive biomarker or monitoring source for checkpoint inhibitor. <h3>Methods</h3> Body including ascites pleural were obtained 55 mGC patients 24 matched blood. VEGF-A, IL-10, TGF-β1 measured profiled by fluorescence assisted cell sorting (FACS). <h3>Results</h3> VEGF-A IL-10 significantly higher...
BVAC-B is an autologous B cell- and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene loaded the natural killer T cell ligand alpha-galactosylceramide. Here, we report first study in patients HER2-positive advanced gastric cancer.
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting (EGFR), human 2 (HER2), and HER4. We present phase Ib/II study of combination varlitinib weekly paclitaxel as second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
In general, expression of transglutaminase 2 (TGase 2) is upregulated in renal cell carcinoma (RCC), resulting p53 instability. Previous studies show that TGase binds to and transports it the autophagosome. Knockdown or inhibition RCC induces p53-mediated apoptosis. Here, we screened a chemical library for inhibitors identified streptonigrin as potential therapeutic compound RCC. Surface plasmon resonance mass spectroscopy were used measure binding 2. Mass spectrometry analysis revealed...
Rho GTPases play a pivotal role in tumor progression by regulating cell migration and invasion.However, the of gastric cancer (GC) remains unexplored.This study aimed to investigate clinical implications RhoJ, which is an uncharted member family.RhoJ expression human GC lines surgical specimens from patients were analyzed.Moreover, vitro gain-of-function analysis was performed evaluate malignant phenotypes RhoJ-overexpressing cells.The extent RhoJ varied among patients.YCC-9 line displayed...
Exosomes are small extracellular vesicles secreted by various types of cells. play an important role in intercellular communication serving as vehicles for transferring proteins, lipids, mRNAs, microRNAs, and DNAs to recipient This study investigated the exosomes gastric cancer aging process using a large number human serum samples from young aged individuals with or without cancer. The age- cancer-associated changes exosome levels exosomal cytokine content were measured. isolated total...
The present study was performed to evaluate the efficacy of circulating cystatin‑C as a tumor monitoring biomarker at different clinical time points in patients with breast cancer over long‑term follow‑up period. In addition, secretory rate from tissue investigated by comparing blood and expression levels cystatin‑C. Blood samples healthy volunteers (40 males 40 females) were obtained yearly health examinations if laboratory imaging abnormalities not detected. 34 205 progression. measured...
Background/Aim: Casein kinase 2 (CK2) is involved in multiple cellular processes. Furthermore, its overexpression several human cancers has been associated with tumor progression. In this study, we evaluated the efficacy of CK2 inhibitor, CX-4945, gastric cancer cell lines and explored potential predictive biomarkers for CX-4945 sensitivity. Materials Methods: The sensitivity to was screened 49 by MTT assay. mRNA protein expression subunits (α α') were determined using qRT-PCR western blot....
Osteosarcoma is the most common primary bone cancer. It can be cured by aggressive surgery and chemotherapy, but outcomes for metastatic or chemoresistant disease remain dismal. Cancer sequencing studies have shown that p53 pathway dysregulated in nearly every case, often translocation; however, no of osteosarcoma evolution intratumor heterogeneity been done to date. We studied a patient with chemoresistant, over course 3 years. performed exome on germline DNA collected from tumor at three...
To identify the anti-cancer effect and investigate underlying mechanism of MPS1/TTK (Monopolar spindle 1; also known as threonine tyrosine kinase) inhibitor in gastric cancer (GC) cell lines.